Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with ...

Axel Stuart Merseburger, MD, PhD, explained that with TKIs like axitinib, it is necessary for oncology nurses to spend time ...

When renal cell cancer is “metastatic,” that means it has spread from your kidney to other parts of your body. Bones are a common place for this cancer to travel. It's harder to treat the ...

For example, a patient experiencing diarrhea, a common side effect of ICI-TKI therapy ... and symptom management of patients with renal cell carcinoma on combined tyrosine kinase and immune ...

Exelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...

Purpose: The role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma (mRCC) is reviewed. Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer ...